Shares of Alpha Cognition Inc. (NASDAQ:ACOG – Get Free Report) passed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $8.78 and traded as low as $8.50. Alpha Cognition shares last traded at $8.73, with a volume of 107,835 shares.
Wall Street Analysts Forecast Growth
ACOG has been the subject of several research analyst reports. Raymond James Financial set a $21.00 target price on Alpha Cognition and gave the company an “outperform” rating in a research note on Thursday. B. Riley Financial began coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They issued a “buy” rating and a $21.00 price target for the company. HC Wainwright upped their price target on shares of Alpha Cognition from $18.00 to $20.00 and gave the company a “buy” rating in a report on Monday, August 17th. Craig Hallum reiterated a “buy” rating and set a $17.00 price objective on shares of Alpha Cognition in a research note on Friday, August 14th. Finally, Wall Street Zen upgraded shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $18.20.
Read Our Latest Research Report on Alpha Cognition
Alpha Cognition Stock Down 0.7%
The company has a fifty day moving average of $8.76 and a two-hundred day moving average of $7.27.
Alpha Cognition (NASDAQ:ACOG – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Alpha Cognition had a negative return on equity of 50.90% and a negative net margin of 147.26%. The firm had revenue of $7.78 million for the quarter, compared to the consensus estimate of $7.04 million. On average, equities analysts anticipate that Alpha Cognition Inc. will post -1.38 EPS for the current year.
Insider Transactions at Alpha Cognition
In other news, Director Robert Wills acquired 10,000 shares of Alpha Cognition stock in a transaction that occurred on Friday, August 21st. The shares were purchased at an average cost of $9.62 per share, for a total transaction of $96,200.00. Following the completion of the purchase, the director directly owned 32,241 shares of the company’s stock, valued at $310,158.42. This trade represents a 44.96% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 8.60% of the stock is owned by company insiders.
Institutional Trading of Alpha Cognition
Several institutional investors have recently added to or reduced their stakes in the business. Pekin Hardy Strauss Inc. bought a new position in shares of Alpha Cognition in the 3rd quarter worth about $210,000. ACT Capital Partners L.P. acquired a new position in shares of Alpha Cognition in the 3rd quarter valued at about $464,000. Aristides Capital LLC grew its position in shares of Alpha Cognition by 1.4% during the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock valued at $1,200,000 after buying an additional 3,052 shares during the last quarter. AWM Investment Company Inc. bought a new stake in shares of Alpha Cognition during the 2nd quarter valued at about $12,073,000. Finally, Opaleye Management Inc. grew its position in shares of Alpha Cognition by 13.0% during the 2nd quarter. Opaleye Management Inc. now owns 2,895,467 shares of the company’s stock valued at $20,905,000 after buying an additional 333,517 shares during the last quarter.
Alpha Cognition Company Profile
Alpha Cognition Inc. is a biopharmaceutical company focused on developing treatments for people with neurodegenerative diseases and cognitive disorders. The company is based in Vancouver, British Columbia. Its lead product, ZUNVEYL (benzgalantamine), is an oral medication approved by the U.S. Food and Drug Administration to treat mild to moderate dementia of the Alzheimer’s type. The company developed benzgalantamine as a prodrug of galantamine. Alpha Cognition is also developing ALPHA-1062 for potential use in other cognitive disorders, including cognitive impairment associated with traumatic brain injury.
Featured Stories
- Five stocks we like better than Alpha Cognition
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.
